

CLAIM AMENDMENTS

1 through 31 (canceled)

1 32. (previously presented) An avipoxvirus grown in avian
2 cells, comprising in the viral genome a Vaccinia virus host range
3 gene selected from the group consisting of C18L, C17L, C7L, K1L,
4 B4R, B23R, and B24R or a homologue of said host range gene and
5 having an increased viral titer compared to that of a corresponding
6 avipoxvirus without said Vaccinia virus host range gene added to
7 said viral genome.

1 33. (previously presented) Avipoxvirus grown in avian
2 cells according to claim 32, wherein the Vaccinia virus host range
3 gene is a host range gene for human cells.

1 34. (previously presented) Avipoxvirus grown in avian
2 cells according to claim 32 or claim 33, wherein the host range
3 gene is selected from the Vaccinia virus genes C7L and K1L.

1 35. (previously presented) Avipoxvirus grown in avian
2 cells according to claim 32, selected from the group consisting of
3 Fowlpoxvirus and Canarypoxvirus.

1 36. (previously presented) Avipoxvirus grown in avian
2 cells according to claim 32 comprising in the viral genome at least
3 one additional heterologous nucleic acid sequence.

1 37. (previously presented) Avipoxvirus grown in avian
2 cells according to claim 36, wherein the additional heterologous
3 nucleic acid sequence is selected from a sequence coding for at
4 least one antigen, antigenic epitope, and/or a therapeutic
5 compound.

1 38. (previously presented) Pharmaceutical composition
2 comprising the avipoxvirus grown in avian cells according to claim
3 32 and a pharmaceutically acceptable carrier, diluent and/or
4 additive.

1 39. (previously presented) Vaccine comprising the
2 avipoxvirus grown in avian cells according to claim 32.

1 40. (Currently amended) The avipoxvirus grown in avian
2 cells according to claim 32, as a drug for effecting an
3 immunological response in a living animal, including a human.

1 41. (withdrawn) Method for introducing a homologous
2 and/or a heterologous nucleic acid sequence into target cells
3 comprising the infection of the target cells with the virus
4 according to claim 36 or claim 37.

1 42. (withdrawn) Method for producing a peptide, protein
2 and/or virus comprising the steps of infection of a host cell with
3 the virus according to claim 32, claim 36 or claim 37, cultivation
4 of the infected host cell under suitable conditions, and isolation
5 and/or enrichment of the peptide and/or protein expressed from the
6 viral genome and/or of the virus produced by said host cell.

1 43. (withdrawn) Method for effecting an immunological
2 response in a living animal body including a human comprising
3 administering the virus according to claim 32, claim 36 or claim 37
4 to the animal or human to be treated.

1 44. (withdrawn) The method according to claim 43,
2 wherein the animal is immuno compromised.

1 45. (previously presented) An isolated avian cell
2 containing the avipoxvirus grown in avian cells according to claim
3 32, claim 36 or claim 37.

1 46. (withdrawn) Method for obtaining the avipoxvirus
2 according to claim 32 comprising the following steps:
3 - introducing an avipoxvirus genome and a DNA comprising a Vaccinia
4 virus host range gene selected from the group consisting of C18L,
5 C17L, C7L, K1L, B4R, B23R, and B24R or a homologue of said host
6 range gene, into avian cells in which the virus is able to

7 reproductively replicate, wherein the DNA is capable to
8 specifically recombine with the genomic DNA of the
9 avipoxvirus-isolating/enriching virus particles comprising the host
10 range gene in the viral genome from these cells.

1 47. (withdrawn) Method for obtaining the avipoxvirus
2 according to claim 36 or claim 37, comprising the following steps:
3 - introducing the genome of an avipoxvirus comprising in
4 the viral genome a Vaccinia virus host range gene selected from the
5 group consisting of C18L, C17L, C7L, K1L, B4R, B23R, and B24R or a
6 homologue of said host range gene and a DNA comprising the at least
7 one additional heterologous sequence into cells in which the virus
8 is able to reproductively replicate, wherein the DNA is capable to
9 specifically recombine with the genomic DNA of the avipoxvirus; and
10 - isolating/enriching virus particles comprising the at
11 least one additional heterologous sequence in the viral genome from
12 these cells.

1 48. (Currently amended) An isolated avian cell, infected
2 with an avipoxvirus grown in avian cells and a Vaccinia virus,
3 wherein the Vaccinia virus comprises at least one Vaccinia host
4 range gene selected from the group consisting of C18L, C17L, C7L,
5 K1L, B4R, B23R, and B24R or a homologue thereof in the vaccinia
6 viral genome and wherein [[the]] a recombinant avipoxvirus, which
7 results from homologous recombination between the avipoxvirus and
8 the vaccinia virus and which contains the vaccinia virus host range

9 gene, has an increased viral titer over that of a corresponding
10 avipoxvirus without said Vaccinia virus host range gene added to
11 said avipox viral genome.

1 49. (previously presented) An isolated avian cell,
2 comprising a Vaccinia virus host range gene selected from the group
3 consisting of C18L, C17L, C7L, K1L, B4R, B23R, and B24R or a
4 homologue of said host range gene, wherein the host range gene or
5 the homologue of said host range gene is not part of a Vaccinia
6 virus genome.

1 50. (previously presented) An isolated avian cell
2 according to claim 48 or claim 49, wherein the host range gene is a
3 Vaccinia virus host range gene selected from the group consisting
4 of C7L, K1L, or a homologue of said host range gene.

1 51. (previously presented) An isolated avian cell
2 according to claim 50, wherein the host range gene is integrated in
3 the cellular genome.

1 52. (previously presented) An isolated avian cell
2 according to claim 50, wherein the host range gene is part of a
3 non-integrated DNA.

1 53. (previously presented) An isolated avian cell
2 according to claim 49, infected with an avipoxvirus grown in avian
3 cells.

1 54. (previously presented) An avian cell according to
2 claim 53, wherein the avipoxvirus grown in avian cells is a
3 recombinant avipoxvirus.

1 55. (previously presented) An avian cell according to
2 claim 54, wherein the host range gene or the homologue of said host
3 range gene is not part of the genome of the Avipoxvirus.

1 56. (previously presented) An avian cell according to
2 claim 45, wherein the cells allow the reproductive replication of
3 the avipoxvirus.

1 57. (withdrawn) Method for increasing the titer of
2 avipoxviruses by infecting cells as defined in claim 49, claim 50,
3 claim 51 or claim 52 with said avipoxvirus, wherein the cells are
4 cells allowing the productive replication of the avipoxvirus.

1 58. (withdrawn) Method for increasing the titer of
2 avipoxviruses by cultivating cells as defined in claim 45, wherein
3 the cells are cells allowing the productive replication of the
4 avipoxvirus.

1 59. (withdrawn) Method for increasing the titer of
2 avipoxviruses by cultivating cells as defined in claim 48, claim
3 53, claim 54 or claim 55 wherein the cells are cells allowing the
4 productive replication of the avipoxvirus.

1 60. (previously presented) Avipoxvirus grown in avian
2 cells according to claim 32 or claim 33, wherein the host range
3 gene is Vaccinia virus gene C7L.